10:17:58 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.

Kalender

2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-13 Ordinarie utdelning NYKD 0.00 NOK
2022-05-12 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning NYKD 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma
2021-12-15 08:25:00
o	Martin Nicklasson proposed as new chairman at Nykode Therapeutics as the
Company enters a new stage of internationalization
o Anders Tuv to continue as an ordinary board member

Oslo, Norway, December 15, 2021 - Nykode Therapeutics (formerly Vaccibody*))
(Euronext Growth (Oslo): VACC (ticker soon to be updated)), a clinical-stage
biopharmaceutical company dedicated to the discovery and development of vaccines
and novel immunotherapies, announced today a proposed election of a new chairman
at an Extraordinary General Meeting (EGM) to be held on December 22, 2021.

Anders Tuv, outgoing chairman of Nykode Therapeutics, said: "Nykode Therapeutics
has over the past two years been on a very successful transformational journey
led by CEO Michael Engsig and his management team, including closing three
significant international collaboration agreements with Adaptive
Biotechnologies, Genentech (part of the Roche group) and Regeneron."

He continued: "The recent name change marks a milestone in the Company's journey
of growth and transformation into a fully-fledged platform company, and that
Nykode Therapeutics now enters a new stage of internationalization, including a
potential US footprint expansion. On this background, I find it the right time
to hand over the reigns as chairman and to continue as an ordinary member of the
board."

Anders Tuv concluded: "I have led the search for my successor, and I am
delighted that Martin Nicklasson has accepted the role as new chairman of Nykode
Therapeutics. Martin Nicklasson is a well-respected and proven chairman and
board member in the biotech and biopharma sector. He brings 40 years of industry
experience of operating across drug development, strategic marketing and
business development, prior to being a highly successful CEO. He has a global
outlook and his extensive career builds on an international set of leadership
experiences with e.g. AstraZeneca and Swedish Orphan Biovitrum, where he
previously held key global leadership roles."

Martin Nicklasson, incoming chairman of Nykode Therapeutics, said: "I am
delighted to join Nykode Therapeutics as new chairman. I am extremely impressed
by the Company's technology platform and R&D pipeline, as well as the Company's
outstanding achievements, including closing three landmark collaboration
agreements over the past fourteen months "

He continued: "I look very much forward to assist in continuing Nykode
Therapeutics' journey of internationalization as well as to further develop
Nykode Therapeutics' position as a leading next-generation immunotherapy
platform company."

Michael Engsig, CEO of Nykode Therapeutics, said: "On behalf of our management
team, I welcome Martin Nicklasson as new chairman of the board of Nykode
Therapeutics. Martin Nicklasson brings valuable strategic insight. His guidance
will help the management team to further drive our continued ambitious plans for
the future, to capitalize on our pipeline, and to fully leverage our unique and
modular vaccine technology platform within multiple, large and commercially
significant disease areas, in line with our corporate strategy. We look very
much forward to the collaboration."

He continued: "On a personal note, I wish to thank Anders warmly for an
outstanding collaboration over the past two years in his capacity as chairman of
Nykode Therapeutics. I am also very pleased that Anders stays on the board and
will continue to deliver significant value to the Company going forward."

Biographical details of the incoming chairman, Martin Nicklasson

Biographical details of Martin Nicklasson include:

o 2009-2010: Swedish Orphan Biovitrum AB